Identification

Name
Halothane
Accession Number
DB01159  (APRD00598, EXPT01754, DB02330)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178)

Structure
Thumb
Synonyms
  • 1-Bromo-1-chloro-2,2,2-trifluoroethane
  • 1,1,1-Trifluoro-2-bromo-2-chloroethane
  • 1,1,1-Trifluoro-2-chloro-2-bromoethane
  • 2-Bromo-2-Chloro-1,1,1-Trifluoroethane
  • 2,2,2-Trifluoro-1-chloro-1-bromoethane
  • Bromochlorotrifluoroethane
  • Ftorotan
  • Halotano
  • Halothane
  • Halothanum
  • Narcotane
  • Phthorothanum
  • Rhodialothan
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fluothane AnestheticLiquidRespiratory (inhalation)Ayerst Laboratories1958-12-311996-09-10Canada
Fluothane Liq Inh 1000mg/gmLiquid1 gRespiratory (inhalation)Wyeth Ayerst Canada Inc.1994-12-311997-08-14Canada
HalothaneSolution99.99 %Respiratory (inhalation)Bimeda Mtc Animal Health Inc1975-12-31Not applicableCanada
Halothane Liq 99.9%Liquid99.9 %Respiratory (inhalation)Halocarbon Laboratories, A Division Of Halocarbon Products Corp.1971-12-312010-06-14Canada
International/Other Brands
Fluothane (Ayerst) / Halotan (Jugoremedija) / Narcotan (Zentiva)
Categories
UNII
UQT9G45D1P
CAS number
151-67-7
Weight
Average: 197.382
Monoisotopic: 195.890225001
Chemical Formula
C2HBrClF3
InChI Key
BCQZXOMGPXTTIC-UHFFFAOYSA-N
InChI
InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H
IUPAC Name
2-bromo-2-chloro-1,1,1-trifluoroethane
SMILES
FC(F)(F)C(Cl)Br

Pharmacology

Indication

For the induction and maintenance of general anesthesia

Structured Indications
Not Available
Pharmacodynamics

Halothane is a general inhalation anesthetic used for induction and maintenance of general anesthesia. It reduces the blood pressure and frequently decreases the pulse rate and depresses respiration. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.

Mechanism of action

Halothane causes general anaethesia due to its actions on multiple ion channels, which ultimately depresses nerve conduction, breathing, cardiac contractility. Its immobilizing effects have been attributed to its binding to potassium channels in cholinergic neurons. Halothane's effect are also likely due to binding to NMDA and calcium channels, causing hyperpolarization.

TargetActionsOrganism
APotassium channel subfamily K member 3
binder
Human
APotassium channel subfamily K member 9
binder
Human
UCalcium-activated potassium channel subunit alpha-1
inhibitor
Human
UGlutamate receptor ionotropic, NMDA 3A
antagonist
Human
UGlutamate receptor ionotropic, NMDA 3B
antagonist
Human
UGlutamate receptor ionotropic, NMDA 2A
antagonist
Human
UGlycine receptor subunit alpha-1
allosteric modulator
Human
URhodopsin
other
Human
UG protein-activated inward rectifier potassium channel 2
inhibitor
Human
UG protein-activated inward rectifier potassium channel 1
inhibitor
Human
UNADH-ubiquinone oxidoreductase chain 1
inhibitor
Human
UIntermediate conductance calcium-activated potassium channel protein 4
inhibitor
Human
UATP synthase subunit delta, mitochondrial
other/unknown
Human
UCalcium-transporting ATPase type 2C member 1
other/unknown
Human
UGamma-aminobutyric acid receptor subunit alpha-1
other/unknown
Human
UGuanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
other/unknown
Human
UNeuropeptide S receptor
other/unknown
Human
AGABA-A receptor (anion channel)
positive allosteric modulator
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Halothane is metabolized in the liver, primarily by CYP2E1, and to a lesser extent by CYP3A4 and CYP2A6.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Toxic effects of halothane include malignant hyperthermia and hepatitis.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Halothane is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Halothane can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Halothane is combined with Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Halothane is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Halothane is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Halothane is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Halothane is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Halothane is combined with Alaproclate.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Halothane is combined with Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Halothane is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Halothane.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Halothane is combined with Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Halothane is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Halothane is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Halothane is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Halothane.Approved, Illicit, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Halothane.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Halothane is combined with Amiloride.Approved
AmiodaroneThe metabolism of Halothane can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Halothane is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Halothane is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Halothane is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Halothane.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Halothane is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Halothane is combined with Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Halothane.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Halothane is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Halothane.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Halothane is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Halothane can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Halothane.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Halothane.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Halothane.Approved, Investigational
ArtemetherThe metabolism of Halothane can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Halothane is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Halothane.Approved
AtazanavirThe metabolism of Halothane can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Halothane is combined with Atenolol.Approved
AtomoxetineThe metabolism of Halothane can be decreased when combined with Atomoxetine.Approved
Atracurium besylateHalothane may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Halothane is combined with Azaperone.Vet Approved
AzelastineHalothane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Halothane is combined with Azilsartan medoxomil.Approved
BaclofenThe risk or severity of adverse effects can be increased when Halothane is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Halothane.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Halothane is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Halothane.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Halothane is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Halothane is combined with Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Halothane is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Halothane.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Halothane is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Halothane.Approved, Withdrawn
BetaxololThe metabolism of Halothane can be decreased when combined with Betaxolol.Approved
BisoprololThe risk or severity of adverse effects can be increased when Halothane is combined with Bisoprolol.Approved
BoceprevirThe metabolism of Halothane can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Halothane can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Halothane can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Halothane is combined with Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Halothane is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Halothane.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Halothane is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Halothane.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Halothane is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Halothane is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Halothane is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Halothane is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Halothane.Approved, Investigational
BuprenorphineHalothane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Halothane can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Halothane.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Halothane.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Halothane is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Halothane is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Halothane is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Halothane is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Halothane.Approved, Illicit, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Halothane is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Halothane is combined with Candesartan.Approved
CanertinibThe risk or severity of adverse effects can be increased when Halothane is combined with Canertinib.Investigational
CapecitabineThe metabolism of Halothane can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Halothane is combined with Captopril.Approved
CarbamazepineThe metabolism of Halothane can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Halothane.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Halothane is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Halothane is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Halothane is combined with Carisoprodol.Approved
CarteololThe risk or severity of adverse effects can be increased when Halothane is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Halothane is combined with Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Halothane can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Halothane can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Halothane is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Halothane is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Halothane.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Halothane is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Halothane is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Halothane can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorphenamine.Approved
ChlorpromazineThe metabolism of Halothane can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Halothane can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Halothane is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Halothane.Approved
CimetidineThe metabolism of Halothane can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Halothane can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Halothane.Approved, Vet Approved
CitalopramThe metabolism of Halothane can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Halothane can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Halothane can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Halothane is combined with Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Halothane is combined with Clidinium.Approved
ClobazamThe metabolism of Halothane can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Halothane.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Halothane is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Halothane can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Halothane is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Halothane is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Halothane is combined with Clopenthixol.Experimental
ClopidogrelThe metabolism of Halothane can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Halothane.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Halothane is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Halothane can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Halothane can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Halothane can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Halothane can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Halothane.Approved, Illicit
ConivaptanThe serum concentration of Halothane can be increased when it is combined with Conivaptan.Approved, Investigational
CrisaboroleThe metabolism of Halothane can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Halothane can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Halothane is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Halothane.Approved
CyclosporineThe metabolism of Halothane can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Halothane is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Halothane can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Halothane can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Halothane is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Halothane is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Halothane.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Halothane is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Halothane can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Halothane can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Halothane can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Halothane can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Halothane can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Halothane is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Halothane.Approved
DesipramineThe metabolism of Halothane can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Halothane is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Halothane is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Halothane is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Halothane is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Halothane.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Halothane is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Halothane.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Halothane is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Halothane.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Halothane is combined with Diclofenamide.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Halothane is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Halothane is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Halothane.Approved, Illicit
DihydroergotamineThe metabolism of Halothane can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Halothane is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Halothane is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Halothane can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Halothane is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Halothane is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Halothane can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Halothane.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Halothane is combined with Dipyridamole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Halothane is combined with Dixyrazine.Experimental
DopamineHalothane may increase the arrhythmogenic activities of Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Halothane is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Halothane can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Halothane is combined with Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Halothane is combined with Doxepin.Approved
DoxorubicinThe metabolism of Halothane can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Halothane can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Halothane is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Illicit
DronedaroneThe metabolism of Halothane can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Halothane is combined with Drotebanol.Experimental, Illicit
DuloxetineHalothane may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Halothane.Approved
EcgonineThe risk or severity of adverse effects can be increased when Halothane is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Halothane is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Halothane is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Halothane.Approved
EliglustatThe metabolism of Halothane can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Halothane is combined with Eltanolone.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Halothane is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Halothane is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Halothane.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Halothane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Halothane is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Halothane can be decreased when it is combined with Enzalutamide.Approved
EphedraEphedra may increase the arrhythmogenic activities of Halothane.Approved, Nutraceutical, Withdrawn
EphedrineEphedrine may increase the arrhythmogenic activities of Halothane.Approved
EpinephrineHalothane may increase the arrhythmogenic activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Halothane is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Halothane.Approved
EprosartanThe risk or severity of adverse effects can be increased when Halothane is combined with Eprosartan.Approved
ErythromycinThe metabolism of Halothane can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Halothane is combined with Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Halothane is combined with Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Halothane.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Halothane.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Halothane is combined with Etacrynic acid.Approved
EthanolHalothane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Halothane.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Halothane is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Halothane is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Halothane is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Halothane is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Halothane is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Halothane is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Halothane is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Halothane is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Halothane is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Halothane.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Halothane is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Halothane is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Halothane can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Halothane is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Halothane is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Halothane is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Halothane is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Halothane.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Halothane.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Halothane is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Halothane.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Halothane is combined with Flibanserin.Approved
FloxuridineThe metabolism of Halothane can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Halothane is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Halothane can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Halothane is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Halothane is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Halothane is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Halothane can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Halothane can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Halothane.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Halothane.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Halothane.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Halothane is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Halothane is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Halothane can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Halothane can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolHalothane may increase the arrhythmogenic activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Halothane can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Halothane can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Halothane is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Halothane.Approved
FospropofolThe risk or severity of adverse effects can be increased when Halothane is combined with Fospropofol.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Halothane is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Halothane can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Halothane.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Halothane is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Halothane.Approved, Illicit
GemfibrozilThe metabolism of Halothane can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Halothane is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Halothane is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Halothane is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Halothane.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Halothane can be decreased when combined with Haloperidol.Approved
HeroinThe risk or severity of adverse effects can be increased when Halothane is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Halothane is combined with Hexobarbital.Approved
HydralazineThe risk or severity of adverse effects can be increased when Halothane is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Halothane is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneHalothane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Halothane is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Halothane.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved
IdelalisibThe serum concentration of Halothane can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Halothane is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Halothane is combined with Iloprost.Approved, Investigational
ImatinibThe metabolism of Halothane can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Halothane is combined with Imidapril.Investigational
ImipramineThe metabolism of Halothane can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Halothane is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Halothane is combined with Indapamide.Approved
IndinavirThe metabolism of Halothane can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Halothane is combined with Indiplon.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Halothane is combined with Indoramin.Withdrawn
IrbesartanThe metabolism of Halothane can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Halothane can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Halothane is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Halothane.Approved, Vet Approved
IsoniazidThe metabolism of Halothane can be decreased when combined with Isoniazid.Approved
IsoprenalineHalothane may increase the arrhythmogenic activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Halothane is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Halothane is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Halothane is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Halothane can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Halothane can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Halothane can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Halothane.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Halothane is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Halothane is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Halothane can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Halothane is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Halothane is combined with Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Halothane is combined with Lamotrigine.Approved, Investigational
LeflunomideThe metabolism of Halothane can be decreased when combined with Leflunomide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Halothane is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Halothane is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Halothane is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Halothane.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Halothane is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Halothane is combined with Levocetirizine.Approved
LevodopaHalothane may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Halothane is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Halothane is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Halothane.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Halothane is combined with Levosimendan.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Halothane.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Halothane is combined with Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Halothane is combined with Lithium.Approved
LobeglitazoneThe metabolism of Halothane can be decreased when combined with Lobeglitazone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Halothane is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Halothane is combined with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Halothane can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Halothane is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Halothane is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Halothane.Approved
LorcaserinThe metabolism of Halothane can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Halothane is combined with Lormetazepam.Approved
LosartanThe metabolism of Halothane can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Halothane can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Halothane.Approved
LuliconazoleThe serum concentration of Halothane can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Halothane can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Halothane can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Halothane.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Vet Approved
ManidipineThe metabolism of Halothane can be decreased when combined with Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Halothane is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Halothane is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Halothane is combined with Mebicar.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Halothane is combined with Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Halothane is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Halothane is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Halothane is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Halothane.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Halothane is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Halothane.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Halothane.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Halothane is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Halothane.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Halothane is combined with Metaxalone.Approved
MethadoneThe metabolism of Halothane can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Halothane is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Halothane is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Halothane is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Halothane is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Halothane is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Halothane.Approved
MethotrimeprazineHalothane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Halothane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Halothane is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Halothane is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Halothane is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Halothane is combined with Methylecgonine.Experimental
MethylphenidateMethylphenidate may increase the hypertensive activities of Halothane.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Halothane.Approved
MetipranololThe risk or severity of adverse effects can be increased when Halothane is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Halothane is combined with Metolazone.Approved
MetoprololThe metabolism of Halothane can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineHalothane may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Halothane.Approved, Illicit
MidostaurinThe metabolism of Halothane can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Halothane can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Halothane is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Halothane is combined with Minoxidil.Approved
MirabegronThe metabolism of Halothane can be decreased when combined with Mirabegron.Approved
MirtazapineHalothane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Halothane can be decreased when it is combined with Mitotane.Approved
MivacuriumHalothane may increase the neuromuscular blocking activities of Mivacurium.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Halothane is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Halothane is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Halothane.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Halothane is combined with Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Halothane is combined with Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Halothane.Approved
NebivololThe risk or severity of adverse effects can be increased when Halothane is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Halothane can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Halothane can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Halothane is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Halothane can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Halothane can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Halothane can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Halothane.Approved
NicotineThe metabolism of Halothane can be decreased when combined with Nicotine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Halothane is combined with Nifedipine.Approved
NilotinibThe metabolism of Halothane can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Halothane is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Halothane is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Halothane is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Halothane.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Halothane is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Halothane is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Halothane is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Halothane is combined with Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Halothane.Approved, Vet Approved
NorepinephrineHalothane may increase the arrhythmogenic activities of Norepinephrine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Halothane is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Halothane is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Halothane is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Halothane is combined with Obinutuzumab.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Halothane.Approved, Investigational
OlaparibThe metabolism of Halothane can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Halothane is combined with Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Halothane is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Halothane can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Halothane.Approved
OpiumThe risk or severity of adverse effects can be increased when Halothane is combined with Opium.Approved, Illicit
OrphenadrineHalothane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Halothane is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Halothane can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Halothane.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Halothane is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Halothane is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Halothane.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Halothane.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Halothane.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Halothane is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Halothane can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Halothane.Approved
PanobinostatThe serum concentration of Halothane can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Halothane is combined with Papaverine.Approved
ParaldehydeHalothane may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Halothane can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Halothane can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Halothane is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Halothane is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Halothane.Approved, Vet Approved
PentobarbitalThe metabolism of Halothane can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved
PerazineThe risk or severity of adverse effects can be increased when Halothane is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Halothane is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Halothane is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Halothane.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Halothane.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Halothane is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Halothane is combined with Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Halothane is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Halothane can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Halothane is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Halothane is combined with Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Halothane is combined with Phenoxyethanol.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Halothane is combined with Phentolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Halothane.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Halothane.Approved
PindololThe risk or severity of adverse effects can be increased when Halothane is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Halothane is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Halothane is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Halothane is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Halothane is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Halothane is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Halothane can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleHalothane may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Halothane is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Halothane is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Halothane is combined with Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Halothane.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Halothane.Approved
PrimidoneThe metabolism of Halothane can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Halothane.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Halothane.Approved, Vet Approved
PromazineThe metabolism of Halothane can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Halothane is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Halothane is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Halothane.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Halothane.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Halothane is combined with Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Halothane is combined with Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Halothane is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Halothane is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Halothane is combined with PSD502.Investigational
PyrimethamineThe metabolism of Halothane can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Halothane can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Halothane.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Halothane is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Halothane can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Halothane can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Halothane is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Halothane is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Halothane is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Halothane is combined with Ramipril.Approved
RanolazineThe metabolism of Halothane can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumHalothane may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Halothane is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Halothane.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Halothane.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Halothane.Approved
RifabutinThe metabolism of Halothane can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Halothane can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Halothane can be increased when combined with Rifapentine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Halothane is combined with Riociguat.Approved
RisperidoneHalothane may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Halothane is combined with Ritanserin.Investigational
RitonavirThe metabolism of Halothane can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Halothane can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Halothane is combined with Romifidine.Vet Approved
RopiniroleHalothane may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Halothane.Approved
RotigotineHalothane may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Halothane.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Halothane is combined with Sacubitril.Approved
SaquinavirThe metabolism of Halothane can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Halothane is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Halothane can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Halothane is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Halothane is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Halothane is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Halothane can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Halothane.Approved, Vet Approved
SildenafilThe metabolism of Halothane can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Halothane can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Halothane can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Halothane is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved
SorafenibThe metabolism of Halothane can be decreased when combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Halothane is combined with Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Halothane is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Halothane can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Halothane can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Halothane is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Halothane.Approved, Investigational
SulfadiazineThe metabolism of Halothane can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Halothane can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Halothane can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Halothane.Approved
SultoprideThe risk or severity of adverse effects can be increased when Halothane is combined with Sultopride.Experimental
SuvorexantHalothane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Halothane is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Halothane is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Halothane is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Halothane can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Halothane can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Halothane is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Halothane.Approved
TerazosinThe risk or severity of adverse effects can be increased when Halothane is combined with Terazosin.Approved
TerbinafineThe metabolism of Halothane can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Halothane is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Halothane is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Halothane is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Halothane is combined with Tetrodotoxin.Investigational
ThalidomideHalothane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Halothane.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Halothane.Approved, Vet Approved
ThioridazineThe metabolism of Halothane can be decreased when combined with Thioridazine.Withdrawn
ThiotepaThe metabolism of Halothane can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Halothane.Approved
TiagabineThe risk or severity of adverse effects can be increased when Halothane is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Halothane is combined with Tiapride.Approved, Investigational
TicagrelorThe metabolism of Halothane can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Halothane can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Halothane is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Halothane is combined with Tilidine.Experimental
TimololThe risk or severity of adverse effects can be increased when Halothane is combined with Timolol.Approved
TipranavirThe metabolism of Halothane can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Halothane is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Halothane can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Halothane is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Halothane can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Halothane is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Halothane is combined with Topiramate.Approved
TopiroxostatThe metabolism of Halothane can be decreased when combined with Topiroxostat.Approved
TorasemideThe risk or severity of adverse effects can be increased when Halothane is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Halothane.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Halothane is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Halothane is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Halothane can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Halothane.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Halothane is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Halothane is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Halothane.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Halothane is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Halothane is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Halothane.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Halothane is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Halothane.Approved, Vet Approved
TrimethoprimThe metabolism of Halothane can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Halothane is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Halothane is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Halothane.Approved, Investigational
ValsartanThe metabolism of Halothane can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe metabolism of Halothane can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Halothane is combined with Veralipride.Experimental
VerapamilThe metabolism of Halothane can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Halothane is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Halothane is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Halothane can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Halothane is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Halothane is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Halothane is combined with Xylazine.Vet Approved
ZafirlukastThe metabolism of Halothane can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Halothane.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Halothane is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Halothane is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Halothane can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Halothane is combined with Zolazepam.Vet Approved
ZolpidemHalothane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Halothane is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Halothane.Approved
ZotepineThe risk or severity of adverse effects can be increased when Halothane is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Halothane.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patents 2,849,502, 2,921,098, 2,959,624, 3,082,263.

General References
  1. Bovill JG: Inhalation anaesthesia: from diethyl ether to xenon. Handb Exp Pharmacol. 2008;(182):121-42. doi: 10.1007/978-3-540-74806-9_6. [PubMed:18175089]
External Links
Human Metabolome Database
HMDB15290
KEGG Drug
D00542
KEGG Compound
C07515
PubChem Compound
3562
PubChem Substance
46506589
ChemSpider
3441
BindingDB
50112212
ChEBI
5615
ChEMBL
CHEMBL931
Therapeutic Targets Database
DAP000692
PharmGKB
PA449845
IUPHAR
2401
Guide to Pharmacology
GtP Drug Page
HET
HLT
RxList
RxList Drug Page
Wikipedia
Halothane
ATC Codes
N01AB01 — Halothane
AHFS Codes
  • 28:04.16 — Inhalation Anesthetics
MSDS
Download (55.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedTreatmentAdjunct to general anesthesia therapy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
LiquidRespiratory (inhalation)
LiquidRespiratory (inhalation)1 g
SolutionRespiratory (inhalation)99.99 %
LiquidRespiratory (inhalation)99.9 %
Prices
Unit descriptionCostUnit
Halothane liquid0.24USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)50-50.5U.S. Patents 2,849,502, 2,921,098, 2,959,624, 3,082,263.
boiling point (°C)50.2 °CPhysProp
water solubility4070 mg/L (at 25 °C)HORVATH,AL ET AL. (1999)
logP2.30HANSCH,C ET AL. (1995)
logS-1.71ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility3.81 mg/mLALOGPS
logP2.5ALOGPS
logP2.12ChemAxon
logS-1.7ALOGPS
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity24.63 m3·mol-1ChemAxon
Polarizability9.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9895
Caco-2 permeable+0.6141
P-glycoprotein substrateNon-substrate0.9007
P-glycoprotein inhibitor INon-inhibitor0.9628
P-glycoprotein inhibitor IINon-inhibitor0.945
Renal organic cation transporterNon-inhibitor0.9183
CYP450 2C9 substrateNon-substrate0.8374
CYP450 2D6 substrateSubstrate0.8031
CYP450 3A4 substrateNon-substrate0.7086
CYP450 1A2 substrateNon-inhibitor0.6027
CYP450 2C9 inhibitorNon-inhibitor0.7607
CYP450 2D6 inhibitorNon-inhibitor0.943
CYP450 2C19 inhibitorNon-inhibitor0.6841
CYP450 3A4 inhibitorNon-inhibitor0.9545
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8808
Ames testNon AMES toxic0.9132
CarcinogenicityCarcinogens 0.711
BiodegradationNot ready biodegradable0.9741
Rat acute toxicity1.7199 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9686
hERG inhibition (predictor II)Non-inhibitor0.9034
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.57 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-014j-2900000000-e961932e23eafc2cc0a5
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as organofluorides. These are compounds containing a chemical bond between a carbon atom and a fluorine atom.
Kingdom
Organic compounds
Super Class
Organohalogen compounds
Class
Organofluorides
Sub Class
Not Available
Direct Parent
Organofluorides
Alternative Parents
Organochlorides / Organobromides / Hydrocarbon derivatives / Alkyl fluorides / Alkyl chlorides / Alkyl bromides
Substituents
Hydrocarbon derivative / Organofluoride / Organochloride / Organobromide / Alkyl halide / Alkyl fluoride / Alkyl chloride / Alkyl bromide / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
haloalkane (CHEBI:5615)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Binder
General Function
S100 protein binding
Specific Function
pH-dependent, voltage-insensitive, background potassium channel protein. Rectification direction results from potassium ion concentration on either side of the membrane. Acts as an outward rectifie...
Gene Name
KCNK3
Uniprot ID
O14649
Uniprot Name
Potassium channel subfamily K member 3
Molecular Weight
43517.665 Da
References
  1. Lazarenko RM, Willcox SC, Shu S, Berg AP, Jevtovic-Todorovic V, Talley EM, Chen X, Bayliss DA: Motoneuronal TASK channels contribute to immobilizing effects of inhalational general anesthetics. J Neurosci. 2010 Jun 2;30(22):7691-704. doi: 10.1523/JNEUROSCI.1655-10.2010. [PubMed:20519544]
  2. Pandit JJ, Buckler KJ: Halothane and sevoflurane exert different degrees of inhibition on carotid body glomus cell intracellular Ca2+ response to hypoxia. Adv Exp Med Biol. 2010;669:201-4. doi: 10.1007/978-1-4419-5692-7_40. [PubMed:20217349]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Binder
General Function
Voltage-gated potassium channel activity
Specific Function
pH-dependent, voltage-insensitive, background potassium channel protein.
Gene Name
KCNK9
Uniprot ID
Q9NPC2
Uniprot Name
Potassium channel subfamily K member 9
Molecular Weight
42263.485 Da
References
  1. Lazarenko RM, Willcox SC, Shu S, Berg AP, Jevtovic-Todorovic V, Talley EM, Chen X, Bayliss DA: Motoneuronal TASK channels contribute to immobilizing effects of inhalational general anesthetics. J Neurosci. 2010 Jun 2;30(22):7691-704. doi: 10.1523/JNEUROSCI.1655-10.2010. [PubMed:20519544]
  2. Pandit JJ, Buckler KJ: Halothane and sevoflurane exert different degrees of inhibition on carotid body glomus cell intracellular Ca2+ response to hypoxia. Adv Exp Med Biol. 2010;669:201-4. doi: 10.1007/978-1-4419-5692-7_40. [PubMed:20217349]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activati...
Gene Name
KCNMA1
Uniprot ID
Q12791
Uniprot Name
Calcium-activated potassium channel subunit alpha-1
Molecular Weight
137558.115 Da
References
  1. Namba T, Ishii TM, Ikeda M, Hisano T, Itoh T, Hirota K, Adelman JP, Fukuda K: Inhibition of the human intermediate conductance Ca(2+)-activated K(+) channel, hIK1, by volatile anesthetics. Eur J Pharmacol. 2000 Apr 28;395(2):95-101. [PubMed:10794813]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein phosphatase 2a binding
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May ...
Gene Name
GRIN3A
Uniprot ID
Q8TCU5
Uniprot Name
Glutamate receptor ionotropic, NMDA 3A
Molecular Weight
125464.07 Da
References
  1. Perouansky M, Kirson ED, Yaari Y: Halothane blocks synaptic excitation of inhibitory interneurons. Anesthesiology. 1996 Dec;85(6):1431-8; discussion 29A. [PubMed:8968191]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Nmda glutamate receptor activity
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine.
Gene Name
GRIN3B
Uniprot ID
O60391
Uniprot Name
Glutamate receptor ionotropic, NMDA 3B
Molecular Weight
112990.98 Da
References
  1. Perouansky M, Kirson ED, Yaari Y: Halothane blocks synaptic excitation of inhibitory interneurons. Anesthesiology. 1996 Dec;85(6):1431-8; discussion 29A. [PubMed:8968191]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
NMDA receptor subtype of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium. Activation requires binding of agonist to both types of sub...
Gene Name
GRIN2A
Uniprot ID
Q12879
Uniprot Name
Glutamate receptor ionotropic, NMDA 2A
Molecular Weight
165281.215 Da
References
  1. Perouansky M, Kirson ED, Yaari Y: Halothane blocks synaptic excitation of inhibitory interneurons. Anesthesiology. 1996 Dec;85(6):1431-8; discussion 29A. [PubMed:8968191]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Transmitter-gated ion channel activity
Specific Function
The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).
Gene Name
GLRA1
Uniprot ID
P23415
Uniprot Name
Glycine receptor subunit alpha-1
Molecular Weight
52623.35 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Schofield CM, Trudell JR, Harrison NL: Alanine-scanning mutagenesis in the signature disulfide loop of the glycine receptor alpha 1 subunit: critical residues for activation and modulation. Biochemistry. 2004 Aug 10;43(31):10058-63. [PubMed:15287733]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Photoreceptor activity
Specific Function
Photoreceptor required for image-forming vision at low light intensity. Required for photoreceptor cell viability after birth. Light-induced isomerization of 11-cis to all-trans retinal triggers a ...
Gene Name
RHO
Uniprot ID
P08100
Uniprot Name
Rhodopsin
Molecular Weight
38892.335 Da
References
  1. Ishizawa Y, Sharp R, Liebman PA, Eckenhoff RG: Halothane binding to a G protein coupled receptor in retinal membranes by photoaffinity labeling. Biochemistry. 2000 Jul 25;39(29):8497-502. [PubMed:10913255]
  2. Keller C, Grimm C, Wenzel A, Hafezi F, Reme C: Protective effect of halothane anesthesia on retinal light damage: inhibition of metabolic rhodopsin regeneration. Invest Ophthalmol Vis Sci. 2001 Feb;42(2):476-80. [PubMed:11157886]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Inward rectifier potassium channel activity
Specific Function
This potassium channel may be involved in the regulation of insulin secretion by glucose and/or neurotransmitters acting through G-protein-coupled receptors. Inward rectifier potassium channels are...
Gene Name
KCNJ6
Uniprot ID
P48051
Uniprot Name
G protein-activated inward rectifier potassium channel 2
Molecular Weight
48450.96 Da
References
  1. Milovic S, Steinecker-Frohnwieser B, Schreibmayer W, Weigl LG: The sensitivity of G protein-activated K+ channels toward halothane is essentially determined by the C terminus. J Biol Chem. 2004 Aug 13;279(33):34240-9. Epub 2004 Jun 2. [PubMed:15175324]
  2. Hara K, Yamakura T, Sata T, Harris RA: The effects of anesthetics and ethanol on alpha2 adrenoceptor subtypes expressed with G protein-coupled inwardly rectifying potassium channels in Xenopus oocytes. Anesth Analg. 2005 Nov;101(5):1381-8. [PubMed:16243998]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
G-protein activated inward rectifier potassium channel activity
Specific Function
This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their...
Gene Name
KCNJ3
Uniprot ID
P48549
Uniprot Name
G protein-activated inward rectifier potassium channel 1
Molecular Weight
56602.84 Da
References
  1. Weigl LG, Schreibmayer W: G protein-gated inwardly rectifying potassium channels are targets for volatile anesthetics. Mol Pharmacol. 2001 Aug;60(2):282-9. [PubMed:11455015]
  2. Yamakura T, Lewohl JM, Harris RA: Differential effects of general anesthetics on G protein-coupled inwardly rectifying and other potassium channels. Anesthesiology. 2001 Jul;95(1):144-53. [PubMed:11465552]
  3. Milovic S, Steinecker-Frohnwieser B, Schreibmayer W, Weigl LG: The sensitivity of G protein-activated K+ channels toward halothane is essentially determined by the C terminus. J Biol Chem. 2004 Aug 13;279(33):34240-9. Epub 2004 Jun 2. [PubMed:15175324]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Nadh dehydrogenase (ubiquinone) activity
Specific Function
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the tra...
Gene Name
MT-ND1
Uniprot ID
P03886
Uniprot Name
NADH-ubiquinone oxidoreductase chain 1
Molecular Weight
35660.055 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Hanley PJ, Ray J, Brandt U, Daut J: Halothane, isoflurane and sevoflurane inhibit NADH:ubiquinone oxidoreductase (complex I) of cardiac mitochondria. J Physiol. 2002 Nov 1;544(Pt 3):687-93. [PubMed:12411515]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein phosphatase binding
Specific Function
Forms a voltage-independent potassium channel that is activated by intracellular calcium (PubMed:26148990). Activation is followed by membrane hyperpolarization which promotes calcium influx. Requi...
Gene Name
KCNN4
Uniprot ID
O15554
Uniprot Name
Intermediate conductance calcium-activated potassium channel protein 4
Molecular Weight
47695.12 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Namba T, Ishii TM, Ikeda M, Hisano T, Itoh T, Hirota K, Adelman JP, Fukuda K: Inhibition of the human intermediate conductance Ca(2+)-activated K(+) channel, hIK1, by volatile anesthetics. Eur J Pharmacol. 2000 Apr 28;395(2):95-101. [PubMed:10794813]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Transporter activity
Specific Function
Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport comp...
Gene Name
ATP5D
Uniprot ID
P30049
Uniprot Name
ATP synthase subunit delta, mitochondrial
Molecular Weight
17489.755 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Signal transducer activity
Specific Function
This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the transport of the calcium.
Gene Name
ATP2C1
Uniprot ID
P98194
Uniprot Name
Calcium-transporting ATPase type 2C member 1
Molecular Weight
100576.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Signal transducer activity
Specific Function
Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity...
Gene Name
GNG2
Uniprot ID
P59768
Uniprot Name
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
Molecular Weight
7850.03 Da
References
  1. Ishizawa Y, Sharp R, Liebman PA, Eckenhoff RG: Halothane binding to a G protein coupled receptor in retinal membranes by photoaffinity labeling. Biochemistry. 2000 Jul 25;39(29):8497-502. [PubMed:10913255]
  2. Zang WJ, Yu XJ, Zang YM: [Effect of halothane on the muscarinic potassium current of the heart]. Sheng Li Xue Bao. 2000 Apr;52(2):175-8. [PubMed:11961592]
  3. Yoshimura H, Jones KA, Perkins WJ, Warner DO: Dual effects of hexanol and halothane on the regulation of calcium sensitivity in airway smooth muscle. Anesthesiology. 2003 Apr;98(4):871-80. [PubMed:12657848]
  4. Streiff J, Jones K, Perkins WJ, Warner DO, Jones KA: Effect of halothane on the guanosine 5' triphosphate binding activity of G-protein alphai subunits. Anesthesiology. 2003 Jul;99(1):105-11. [PubMed:12826849]
  5. Milovic S, Steinecker-Frohnwieser B, Schreibmayer W, Weigl LG: The sensitivity of G protein-activated K+ channels toward halothane is essentially determined by the C terminus. J Biol Chem. 2004 Aug 13;279(33):34240-9. Epub 2004 Jun 2. [PubMed:15175324]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Vasopressin receptor activity
Specific Function
G-protein coupled receptor for neuropeptide S (NPS) (PubMed:16790440). Promotes mobilization of intracellular Ca(2+) stores (PubMed:16790440). Inhibits cell growth in response to NPS binding (PubMe...
Gene Name
NPSR1
Uniprot ID
Q6W5P4
Uniprot Name
Neuropeptide S receptor
Molecular Weight
42686.28 Da
References
  1. Ishizawa Y, Sharp R, Liebman PA, Eckenhoff RG: Halothane binding to a G protein coupled receptor in retinal membranes by photoaffinity labeling. Biochemistry. 2000 Jul 25;39(29):8497-502. [PubMed:10913255]
  2. Ishizawa Y, Pidikiti R, Liebman PA, Eckenhoff RG: G protein-coupled receptors as direct targets of inhaled anesthetics. Mol Pharmacol. 2002 May;61(5):945-52. [PubMed:11961111]
  3. Streiff J, Jones K, Perkins WJ, Warner DO, Jones KA: Effect of halothane on the guanosine 5' triphosphate binding activity of G-protein alphai subunits. Anesthesiology. 2003 Jul;99(1):105-11. [PubMed:12826849]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Restrepo JG, Garcia-Martin E, Martinez C, Agundez JA: Polymorphic drug metabolism in anaesthesia. Curr Drug Metab. 2009 Mar;10(3):236-46. [PubMed:19442086]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Spracklin DK, Hankins DC, Fisher JM, Thummel KE, Kharasch ED: Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J Pharmacol Exp Ther. 1997 Apr;281(1):400-11. [PubMed:9103523]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Restrepo JG, Garcia-Martin E, Martinez C, Agundez JA: Polymorphic drug metabolism in anaesthesia. Curr Drug Metab. 2009 Mar;10(3):236-46. [PubMed:19442086]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Restrepo JG, Garcia-Martin E, Martinez C, Agundez JA: Polymorphic drug metabolism in anaesthesia. Curr Drug Metab. 2009 Mar;10(3):236-46. [PubMed:19442086]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Details
1. Serum albumin
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Sawas AH, Pentyala SN, Rebecchi MJ: Binding of volatile anesthetics to serum albumin: measurements of enthalpy and solvent contributions. Biochemistry. 2004 Oct 5;43(39):12675-85. [PubMed:15449957]

Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13